{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:55:40Z","timestamp":1782233740913,"version":"3.54.5"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Center Research and Development Fund of Japan","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"name":"National Cancer Center Research and Development Fund of Japan","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund of Japan","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paclitaxel is a standard first-line chemotherapy for primary cutaneous angiosarcoma. However, there is no established second-line treatment after paclitaxel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate in the JCOG1605 study the efficacy and safety of second-line pazopanib for primary cutaneous angiosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-institutional single-arm confirmatory trial was conducted in Japan. Patients with cutaneous angiosarcoma not associated with lymphoedema or radiation exposure were included. Pazopanib was administered orally at an initial dose of 800\u2005mg once daily. The primary endpoint was progression-free survival (PFS). Retrospective data on second-line docetaxel following first-line paclitaxel treatment were used as the historical control. This trial was registered with the UMIN Clinical Trials Registry (UMIN000031438; http:\/\/www.umin.ac.jp\/ctr\/index.htm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were enrolled from 15 institutions and received pazopanib. The median PFS and overall survival (OS) were 2.8\u2005months [80% confidence interval (CI) 2.1\u20133.9] and 12.1\u2005months (95% CI 8.9\u201328.8), respectively. The response and disease control rates were 31.8% (95% CI 13.9\u201354.9) and 63.6% (95% CI 40.7\u201382.8), respectively. Twenty-eight (93%) and 21 (70%) patients experienced grade \u2265 2 and grade \u2265 3 nonhaematological adverse events, respectively. No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The primary endpoint (PFS) did not meet the predefined threshold. However, the response rate and OS were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with primary cutaneous angiosarcoma previously treated with paclitaxel.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag071","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:23:08Z","timestamp":1772454188000},"page":"27-37","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of pazopanib in patients in Japan with primary cutaneous angiosarcoma pretreated with paclitaxel: results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)"],"prefix":"10.1093","volume":"195","author":[{"given":"Kohei","family":"Oashi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Saitama Cancer Center , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-7100","authenticated-orcid":false,"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-8712","authenticated-orcid":false,"given":"Yusuke","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Hiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-8182","authenticated-orcid":false,"given":"Eiji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4471-1635","authenticated-orcid":false,"given":"Takuya","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kiniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-4773","authenticated-orcid":false,"given":"Takuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikko","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026062312171919300_ljag071-B1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12885-020-07136-1","article-title":"A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)","volume":"20","author":"Oashi","year":"2020","journal-title":"BMC Cancer"},{"key":"2026062312171919300_ljag071-B2","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026062312171919300_ljag071-B3","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","article-title":"Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face","volume":"86","author":"Fata","year":"1999","journal-title":"Cancer"},{"key":"2026062312171919300_ljag071-B4","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026062312171919300_ljag071-B5","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"2026062312171919300_ljag071-B6","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","article-title":"Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group","volume":"44","author":"Schlemmer","year":"2008","journal-title":"Eur J Cancer"},{"key":"2026062312171919300_ljag071-B7","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/bjd.13110","article-title":"Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study","volume":"171","author":"Fujisawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026062312171919300_ljag071-B8","first-page":"114","article-title":"Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma","volume":"27","author":"Roy","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026062312171919300_ljag071-B9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"2026062312171919300_ljag071-B10","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jaad.2013.08.055","article-title":"Angiosarcoma of the scalp successfully treated with pazopanib","volume":"70","author":"Tomita","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026062312171919300_ljag071-B11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ced.12646","article-title":"Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma","volume":"40","author":"Kitamura","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"2026062312171919300_ljag071-B12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1684\/ejd.2014.2451","article-title":"Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib","volume":"25","author":"Fujiwara","year":"2015","journal-title":"Eur J Dermatol"},{"key":"2026062312171919300_ljag071-B13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12032-016-0831-z","article-title":"Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma","volume":"33","author":"Ogata","year":"2016","journal-title":"Med Oncol"},{"key":"2026062312171919300_ljag071-B14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"2026062312171919300_ljag071-B15","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026062312171919300_ljag071-B16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026062312171919300_ljag071-B17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"Nakamura","year":"2016","journal-title":"Cancer"},{"key":"2026062312171919300_ljag071-B18","author":"Ministry of Health, Labour and Welfare"},{"key":"2026062312171919300_ljag071-B19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026062312171919300_ljag071-B20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Kollar","year":"2017","journal-title":"Acta Oncol"},{"key":"2026062312171919300_ljag071-B21","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/cncr.34403","article-title":"OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma","volume":"128","author":"Thiebaud","year":"2022","journal-title":"Cancer"},{"key":"2026062312171919300_ljag071-B22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol"},{"key":"2026062312171919300_ljag071-B23","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial","volume":"33","author":"Ray Coquard","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026062312171919300_ljag071-B24","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026062312171919300_ljag071-B25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"key":"2026062312171919300_ljag071-B26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2021.06.027","article-title":"An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma","volume":"154","author":"Agulnik","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026062312171919300_ljag071-B27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/cancers13061223","article-title":"Treatment of angiosarcoma with pazopanib and paclitaxel: results of the EVA (Evaluation of Votrient\u00ae in Angiosarcoma) phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06)","volume":"13","author":"Pink","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062312171919300_ljag071-B28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026062312171919300_ljag071-B29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/oncolo\/oyac155","article-title":"Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma","volume":"27","author":"Riedel","year":"2022","journal-title":"Oncologist"},{"key":"2026062312171919300_ljag071-B30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"key":"2026062312171919300_ljag071-B31","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1158\/1078-0432.CCR-25-0311","article-title":"Cemiplimab in locally advanced or metastatic secondary angiosarcomas (CEMangio): A Phase II clinical trial and biomarker analyses","volume":"31","author":"van Ravensteijn","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062312171919300_ljag071-B32","doi-asserted-by":"crossref","first-page":"115537","DOI":"10.1016\/j.ejca.2025.115537","article-title":"Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: efficacy of nivolumab (AngioCheck Study)","volume":"224","author":"Fujisawa","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026062312171919300_ljag071-B33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026062312171919300_ljag071-B34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026062312171919300_ljag071-B35","doi-asserted-by":"crossref","first-page":"e002990","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062312171919300_ljag071-B36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026062312171919300_ljag071-B37","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","article-title":"Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma","volume":"13","author":"D'Angelo","year":"2022","journal-title":"Nat Commun"},{"key":"2026062312171919300_ljag071-B38","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO-24-02524","article-title":"Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with relapsed\/refractory metastatic sarcomas","volume":"43","author":"Wilky","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062312171919300_ljag071-B39","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026062312171919300_ljag071-B40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","article-title":"Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial","volume":"15","author":"Cho","year":"2024","journal-title":"Nat Commun"},{"key":"2026062312171919300_ljag071-B41","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"2026062312171919300_ljag071-B42","article-title":"The efficacy and safety of pazopanib as a second-line treatment for patients with paclitaxel-pretreated primary cutaneous angiosarcoma \u2013 results of JCOG1605 study","volume":"3","author":"Oashi","year":"2025","journal-title":"EJC Skin Cancer"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag071\/67204680\/ljag071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/1\/27\/67204680\/ljag071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/1\/27\/67204680\/ljag071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:17:28Z","timestamp":1782231448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/1\/27\/8503879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag071","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,3]]}}}